Compare Bristol-Myers Squibb Co (BMY) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Synchrony Financial — how do they compare? Bristol-Myers Squibb Co trades at $64.82 (market cap $130.12B), while Synchrony Financial trades at $79.87 (market cap $25.84B). The key difference: Bristol-Myers Squibb Co is far larger — about 5× Synchrony Financial's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | SYF | |
|---|---|---|
Market Cap | $130.12B | $25.84B |
Sector | Health | Financials |
52-Week High | $65.89 | $88.47 |
52-Week Low | $42.60 | $63.78 |
Enterprise Value | $164.11B | — |
Dividend Yield | 3.96% | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BMY trades at $64.65, up 1.63% with bullish technical signals and strong fundamentals. The stock shows robust profitability with 18.87% net margin and 46.7% ROE, supported by recent FDA approval for ZENBEXUS therapy and consistent earnings beats. Valuation remains reasonable with P/E of 14.03 and P/S of 2.65. Analyst consensus price target stands at $68.56 with 45% buy ratings.
BMY presents a compelling investment case with strong growth portfolio offsetting patent cliffs, though risks include legal challenges and debt levels. The stock's current valuation and recent positive developments suggest potential upside toward analyst targets, balanced by competitive pressures in the biopharma sector.
Synchrony Financial (SYF) trades at $79.41, up 1.2% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $86.33. The company reported strong Q2 2026 earnings of $2.59 per share, beating estimates, and maintains robust profitability with a 23.4% net income margin. Recent news highlights strategic initiatives, including the appointment of a Chief AI Officer and a partnership with Stripe to expand CareCredit financing access.
SYF presents a compelling investment case with attractive valuation multiples, consistent earnings beats, and shareholder-friendly capital returns via buybacks and dividends. Key risks include potential consumer credit deterioration amid economic uncertainty and increased investing cash outflows. The stock's upside is supported by solid fundamentals and positive analyst sentiment, though investors should monitor credit trends and spending patterns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
